

BIOMARIN PHARMACEUTICAL INC

Form 4

February 10, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
SPIEGELMAN DANIEL K

2. Issuer Name and Ticker or Trading Symbol  
BIOMARIN PHARMACEUTICAL INC [BMRN]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)  
105 DIGITAL DRIVE  
(Street)

3. Date of Earliest Transaction (Month/Day/Year)  
03/18/2013

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
EVP, Chief Financial Officer

NOVATO, CA 94949

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	03/18/2013	03/18/2013	A <sup>(1)</sup>	7	A \$ 61.4829	68,683	D
Common Stock	03/18/2013	03/18/2013	A <sup>(1)</sup>	7	A \$ 61.3814	68,690	D
Common Stock	03/20/2013	03/20/2013	A <sup>(1)</sup>	5	A \$ 61.988	68,695	D
Common Stock	03/20/2013	03/20/2013	A <sup>(1)</sup>	4	A \$ 61.4325	68,699	D
Common Stock	06/19/2013	06/19/2013	A <sup>(1)</sup>	9	A \$ 58.5678	68,708	D

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Common Stock	06/19/2013	06/19/2013	<u>A<sup>(1)</sup></u>	9	A	\$ 58.8478	68,717	D
Common Stock	09/10/2013	09/10/2013	<u>A<sup>(1)</sup></u>	8	A	\$ 70.0583	68,725	D
Common Stock	09/10/2013	09/10/2013	<u>A<sup>(1)</sup></u>	7	A	\$ 70.3029	68,732	D
Common Stock	10/04/2013	10/04/2013	<u>A<sup>(1)</sup></u>	5	A	\$ 74.074	68,737	D
Common Stock	10/07/2013	10/07/2013	<u>A<sup>(1)</sup></u>	6	A	\$ 74.8383	68,743	D
Common Stock	10/30/2013	10/30/2013	<u>A<sup>(1)</sup></u>	4	A	\$ 66.475	68,747	D
Common Stock	10/30/2013	10/30/2013	<u>A<sup>(1)</sup></u>	5	A	\$ 65.75	68,752	D
Common Stock	11/20/2013	11/20/2013	<u>A<sup>(1)</sup></u>	8	A	\$ 65.8863	68,760	D
Common Stock	03/05/2014	03/05/2014	<u>S<sup>(1)(2)</sup></u>	12	D	\$ 82.9258	68,748	D
Common Stock	05/02/2014	05/02/2014	<u>S<sup>(1)</sup></u>	3	D	\$ 58.0233	68,745	D
Common Stock	05/02/2014	05/02/2014	<u>S<sup>(1)</sup></u>	8	D	\$ 58.78	68,737	D
Common Stock	08/06/2014	08/06/2014	<u>A<sup>(1)</sup></u>	7	A	\$ 62.1671	68,744	D
Common Stock	08/06/2014	08/06/2014	<u>A<sup>(1)</sup></u>	7	A	\$ 62.1771	68,751	D
Common Stock	09/03/2014	09/03/2014	<u>S<sup>(1)(2)</sup></u>	9	D	\$ 69.8289	68,742	D
Common Stock	09/03/2014	09/03/2014	<u>S<sup>(1)(2)</sup></u>	9	D	\$ 69.7011	68,733	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene
--	------------------------------------	--------------------------------------	--	--------------------------------	-------------------------	--	--	--	------------------------

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 4

Derivative Security	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	V		Date Exercisable	Expiration Date	Title	Amount or Number of Shares	(Instr. 3 and 4)
			(A)	(D)					

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
SPIEGELMAN DANIEL K 105 DIGITAL DRIVE NOVATO, CA 94949			EVP, Chief Financial Officer	

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact	02/10/2015
**Signature of Reporting Person	Date

Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Inadvertent transaction not directed by the reporting person through a broker-administered investment pool.
- (2) Some of the transactions executed as reported herein resulted in a short swing profit under Section 16(b) of the Securities Exchange Act of 1934, as amended ("Section 16(b)"). The Reporting Person has made arrangements with the Issuer to disgorge short swing profits realized to the Issuer, and upon settlement, the Reporting Person will have discharged in full any obligation under Section 16(b) with respect to the reported transactions.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.